The EC has granted expanded approval to BMS' Breyanzi, to treat adults with relapsed or refractory follicular lymphoma (FL).
Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...
CTA approval marks Anocca’s transition to a clinical-stage companyFirst-in-human VIDAR-1 trial begins with the deployment of ...
AstraZeneca bought Belgian biotech company EsoBiotec in a deal valued at up to $1 billion, to expand its cell-therapy portfolio.
AstraZeneca will acquire EsoBiotec for a total consideration of up to $1billion, on a cash and debt free basis. This will ...
AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1,000m, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, ...
The tumult of large-scale cuts to federal spending, pullbacks of civil rights protections, and new tariffs getting announced ...
Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...
Inter-atrial shunt device therapy has shown mixed results in clinical trials, with clinical 'non-responders' typically showing features of more advanced heart failure. We aimed to analyse the ...
Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for ...
Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...
Ashton had been tormented by fear that he would be rejected by his family in the weeks leading up to his coming out in 2012.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results